ReviewBiomarker research2021
Next frontier in tumor immunotherapy: macrophage-mediated immune evasion.
Review in Biomarker research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
92 citing papers in PubMed, 127 citations in OpenAlex.
- Exosomal delivery of METTL3 promotes M1 macrophage polarization by inducing miR-155-5p maturation via m6A modification.Annals of medicine · 2026Article
- Prognostic significance of pre-intervention circulating cytokines in digestive system cancers: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Potassium channels in cancer: from hallmarks to therapeutic targeting.Journal of physiology and biochemistry · 2026Review
- Cation homeostasis-related prognostic genes uncovered by transcriptomic analysis in breast cancer.Translational cancer research · 2026Article
- Dual PD-1/IL-2Rα targeting restores CD8Cell reports. Medicine · 2026Article
- A risk score model based on glycosylation-related genes for predicting radioresistance and prognosis of lung adenocarcinoma.Translational cancer research · 2026Article
- Immune checkpoint inhibitors in dMMR-MSI-H colorectal cancer: rationale, progress and prospects.Frontiers in immunology · 2026Review
- Macrophages in obesity-related breast cancer: mechanistic insights and therapeutic opportunities.Breast cancer research : BCR · 2025Review
- Minimal Residual Disease in Breast Cancer: Tumour Microenvironment Interactions, Detection Methods and Therapeutic Approaches.International journal of molecular sciences · 2025Review
- The role of GPD2 and glycolysis-related genes in cholangiocarcinoma: insights into prognostic biomarkers and tumor-immune interactions.Cancer cell international · 2025Article
- Targeting the CD47-SIRPalpha checkpoint in multiple myeloma.Discover oncology · 2025Review
- CDH3 promotes the progression of lung adenocarcinoma through driving epithelial-mesenchymal transition progress.Journal of translational medicine · 2025Article
- Engineering multifunctional surface topography to regulate multiple biological responses.Biomaterials · 2025Review
- Fibroblast Activation Protein (FAP)Oncogene · 2025Article
- Review
- Prognostic model identification of ribosome biogenesis-related genes in pancreatic cancer based on multiple machine learning analyses.Discover oncology · 2025Article
- Mefloquine Suppresses Metastasis in Renal Cell Carcinoma Through Targeting SPC25.Cancer science · 2025Article
- Liquiritin improves macrophage degradation of engulfed tumour cells by promoting the formation of phagolysosomes via NOX2/gp91phox.Journal of pharmaceutical analysis · 2025Article
- The emerging functions and clinical implications of circRNAs in acute myeloid leukaemia.Cancer cell international · 2025Review
- Causal association between immune cell phenotypes and colorectal cancer: a two-sample bidirectional Mendelian randomization analysis.Discover oncology · 2025Article
32 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
Tumor-associated macrophages (TAMs), at the core of immunosuppressive cells and cytokines networks, play a crucial role in tumor immune evasion. Increasing evidences suggest that potential mechanisms of macrophage-mediated tumor immune escape imply interpretation and breakthrough to bottleneck of current tumor immunotherapy. Therefore, it is pivotal to understand the interactions between macrophages and other immune cells and factors for enhancing existing anti-cancer treatments. In this review, we focus on the specific signaling pathways through which TAMs involve in tumor antigen recognition disorders, recruitment and function of immunosuppressive cells, secretion of immunosuppressive cytokines, crosstalk with immune checkpoints and formation of immune privileged sites. Furthermore, we summarize correlative pre-clinical and clinical studies to provide new ideas for immunotherapy. From our perspective, macrophage-targeted therapy is expected to be the next frontier of cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.